FibroGen, Inc (NASDAQ:FGEN) saw some unusual options trading activity on Wednesday. Investors purchased 956 put options on the company. This is an increase of approximately Infinity compared to the typical volume of 0 put options.
In related news, insider K Peony Yu sold 7,500 shares of the company’s stock in a transaction dated Monday, August 21st. The shares were sold at an average price of $41.03, for a total transaction of $307,725.00. Following the completion of the sale, the insider now owns 191,507 shares of the company’s stock, valued at $7,857,532.21. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Thomas F. Kearns, Jr. sold 18,000 shares of the company’s stock in a transaction dated Wednesday, November 15th. The stock was sold at an average price of $45.22, for a total transaction of $813,960.00. Following the sale, the director now directly owns 156,564 shares of the company’s stock, valued at approximately $7,079,824.08. The disclosure for this sale can be found here. In the last three months, insiders sold 463,018 shares of company stock valued at $23,969,116. 14.90% of the stock is currently owned by company insiders.
Hedge funds have recently bought and sold shares of the company. Quantbot Technologies LP bought a new position in shares of FibroGen in the second quarter worth about $128,000. Oppenheimer Asset Management Inc. lifted its holdings in shares of FibroGen by 112.6% in the third quarter. Oppenheimer Asset Management Inc. now owns 4,410 shares of the biopharmaceutical company’s stock worth $237,000 after acquiring an additional 2,336 shares during the last quarter. Ameritas Investment Partners Inc. lifted its holdings in shares of FibroGen by 15.4% in the second quarter. Ameritas Investment Partners Inc. now owns 5,218 shares of the biopharmaceutical company’s stock worth $169,000 after acquiring an additional 696 shares during the last quarter. BBR Partners LLC bought a new position in shares of FibroGen in the third quarter worth about $299,000. Finally, Teacher Retirement System of Texas bought a new position in shares of FibroGen in the third quarter worth about $299,000. 46.93% of the stock is owned by hedge funds and other institutional investors.
FibroGen (FGEN) opened at $46.87 on Friday. The company has a current ratio of 10.83, a quick ratio of 10.83 and a debt-to-equity ratio of 0.16. FibroGen has a fifty-two week low of $19.25 and a fifty-two week high of $60.15.
FGEN has been the subject of several recent analyst reports. Stifel Nicolaus reaffirmed a “buy” rating and set a $80.00 price objective on shares of FibroGen in a research report on Thursday, September 14th. Jefferies Group LLC reaffirmed a “buy” rating and set a $75.00 price objective on shares of FibroGen in a research report on Tuesday, September 12th. BidaskClub cut shares of FibroGen from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Mizuho reaffirmed a “hold” rating and set a $61.00 price objective on shares of FibroGen in a research report on Thursday, November 9th. Finally, Goldman Sachs Group, Inc. (The) cut shares of FibroGen from a “buy” rating to a “neutral” rating and set a $31.00 price objective for the company. in a research report on Friday, July 21st. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. FibroGen presently has an average rating of “Buy” and an average price target of $65.67.
COPYRIGHT VIOLATION WARNING: “FibroGen Sees Unusually Large Options Volume (FGEN)” was originally published by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this news story on another publication, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be accessed at https://stocknewstimes.com/2017/11/18/fibrogen-sees-unusually-large-options-volume-fgen.html.
FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.
Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.